These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38784576)

  • 1. A novel multivariate logistic model for predicting risk factors of failed treatment with carbapenem-resistant
    Sun K; Peng F; Xu K; Liu Y; Zhou X; Shang N; Li C
    Front Public Health; 2024; 12():1385118. PubMed ID: 38784576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study.
    Thatrimontrichai A; Techato C; Dissaneevate S; Janjindamai W; Maneenil G; Kritsaneepaiboon S; Tanaanantarak P
    J Infect Chemother; 2016 Jul; 22(7):444-9. PubMed ID: 27229539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
    Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
    Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventilator-Associated Pneumonia due to Drug-Resistant
    Čiginskienė A; Dambrauskienė A; Rello J; Adukauskienė D
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30781896
    [No Abstract]   [Full Text] [Related]  

  • 6. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
    Schafer JJ; Goff DA; Stevenson KB; Mangino JE
    Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.
    Cikman A; Gulhan B; Aydin M; Ceylan MR; Parlak M; Karakecili F; Karagoz A
    Int J Med Sci; 2015; 12(9):695-700. PubMed ID: 26392806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a Medical Intensive Care Unit of University Hospital in Thailand.
    Inchai J; Liwsrisakun C; Theerakittikul T; Chaiwarith R; Khositsakulchai W; Pothirat C
    J Infect Chemother; 2015 Aug; 21(8):570-4. PubMed ID: 26026660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of extended-infusion of carbapenem plus sulbactam for ventilator-associated pneumonia caused by extensive drug-resistant
    Wang X; Hu Y; Que CL; Zhang H; Huang JJ; Cao J; Jin Z; Wang GF; Zhang W
    Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):2996-3000. PubMed ID: 29061006
    [No Abstract]   [Full Text] [Related]  

  • 10. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.
    Chan JD; Graves JA; Dellit TH
    J Intensive Care Med; 2010; 25(6):343-8. PubMed ID: 20837632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.
    Russo A; Gullì SP; D'Avino A; Borrazzo C; Carannante N; Dezza FC; Covino S; Polistina G; Fiorentino G; Trecarichi EM; Mastroianni CM; Torti C; Oliva A
    Int J Antimicrob Agents; 2024 Jul; 64(1):107190. PubMed ID: 38697579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk factors and resistance patterns of invasive
    Ge YL; Shan QW; Qiu Y; Zhou SP; Cheng YB; Wang F; Yang JW; Wan CM; Zhu Y; Xu Y; Chen MX; Lin DJ; Zhu CH; Zeng M
    Zhonghua Er Ke Za Zhi; 2022 Aug; 60(8):762-768. PubMed ID: 35922185
    [No Abstract]   [Full Text] [Related]  

  • 13. [Carbapenem restriction reduce the incidence of multidrug-resistant Acinetobacter baumannii in ventilator associated pneumonia].
    Xue XS; Wang B; Deng LJ; Kang Y
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Apr; 21(4):234-6. PubMed ID: 19374793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam.
    Zalts R; Neuberger A; Hussein K; Raz-Pasteur A; Geffen Y; Mashiach T; Finkelstein R
    Am J Ther; 2016; 23(1):e78-85. PubMed ID: 24263165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study.
    Oliva A; Liguori L; Covino S; Petrucci F; Cogliati-Dezza F; Curtolo A; Savelloni G; Comi M; Sacco F; Ceccarelli G; Viscido A; Alessandri F; Raponi G; Pugliese F; Mastroianni CM; Venditti M
    Eur J Clin Microbiol Infect Dis; 2024 Jun; 43(6):1149-1160. PubMed ID: 38634975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
    Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant
    Zhang Y; Xu G; Miao F; Huang W; Wang H; Wang X
    Front Public Health; 2023; 11():1282413. PubMed ID: 38098829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination eravacycline therapy for ventilator-associated pneumonia due to carbapenem-resistant Acinetobacter baumannii in patients with COVID-19: A case series.
    Jackson MNW; Wei W; Mang NS; Prokesch BC; Ortwine JK
    Pharmacotherapy; 2024 Apr; 44(4):301-307. PubMed ID: 38270447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
    Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
    Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanical ventilation-associated pneumonia caused by Acinetobacter baumannii in Northeast China region: analysis of genotype and drug resistance of bacteria and patients' clinical features over 7 years.
    Zhang T; Xu X; Xu CF; Bilya SR; Xu W
    Antimicrob Resist Infect Control; 2021 Sep; 10(1):135. PubMed ID: 34526127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.